EHS
EHS

FDA Warns of Decreased Survival in Some UC Patients on Keytruda or Tecentriq

The FDA issued an alert about decreased survival associated with the use of pembrolizumab (Keytruda, Merck) or atezolizumab (Tecentriq, Genentech) as monotherapy in previously untreated patients with metastatic urothelial cancer and low programmed death ligand-1 expression.
EHS
Back to top button